The Global "Rosacea Therapeutics Market" is expected to grow at a high CAGR during the forecasting period (2022-2029).
Rosacea is a long-term skin condition that typically affects the face. It can result in pimples, redness, swelling, and superficial dilated blood vessels. Often, the nose, forehead, cheeks, and chin are most involved. The cause of rosacea is unknown, but the risk factors are believed to include a family history of the condition. While not curable, treatment usually improves symptoms. There are four subtypes of rosacea, and it is possible to have more than one subtype of rosacea at a time.
The subtypes are –
The global Rosacea Therapeutics market is primarily driven by the high prevalence of Rosacea, robust pipeline of the treatment drugs coupled with the increasing awareness of the disorder and its treatments. According to a study conducted by the National Rosacea Society Study, an estimated 415 million people are affected by Rosacea worldwide. Moreover, personal appearance holds a great deal of importance to virtually all individuals, and rosacea has a negative impact on psychological, social, and occupational interactions adults with acne face higher rates of unemployment than the general population. According to the National Rosacea Society’s survey conducted in the U.S., it was found that over 90.0% of the patients afflicted with Rosacea suffered from low self-esteem and self-confidence. Hence, the increasing emotional burden of this condition is a crucial factor driving the global rosacea therapeutics market.
However, high penetration of generic medication due to patent expiries and off-label usage of medicines may hinder the growth of the global market.
By Mode of Administration, the global Rosacea Therapeutics market is bifurcated into Topical and Oral. Topical drugs dominate the rosacea treatment, accounting for more than 50% of the market. It can be attributed to Topical medications generally being prescribed as the first-line of treatment form. Topical drugs are highly favored over other options because they are convenient, give better results and can be used in combination with oral medications depending upon disease severity.
By Drug Class, the global Rosacea Therapeutics market is segmented into Antimicrobials, Alpha Agonists, Retinoids, and others. Antimicrobials hold the most substantial market share in the drug class as antimicrobial drugs are typically the first line of treatment. Antibiotics help reduce some types of bacteria but likely mainly fight inflammation when used for this disease.
Antibiotics that are often used to treat rosacea include oxytetracycline, tetracycline, doxycycline, and erythromycin. Additionally, sulfacetamide products and azelaic acid are also recommended in the treatment. Alpha agonists are the fastest-growing share in drug class owing to their quick relief and new drug launches. For instance, recent studies have shown the drug brimonidine (Mirvaso) is effective in reducing redness and results are seen within 12 hours after application of the gel. In January 2017, Allergan announced the approval of RHOFADE cream by the U.S. FDA for the topical treatment of persistent facial erythema associated with rosacea in adults.
Geographically, the global Rosacea Therapeutics market is divided into North America, Europe, South America, Asia-Pacific, and the Middle East and Africa.
North America and Europe dominate the global Rosacea Therapeutics market owing to the high prevalence of the disorders in the regions. The National Institutes of Health stated that rosacea is a condition more common in people of western and northern European descent due to Caucasians with fair sun-sensitive skin having the highest risk for rosacea. As a result, it is prevalent mostly in the EU and the US. According to the National Rosacea Society (NRS), 16 million suffer from the signs and symptoms of rosacea, and millions more may be in temporary remission in the U.S. A prospective study from Germany reported an overall rosacea prevalence of 12, with erythematotelangiectatic and papulopustular subtypes making up 9% and 3% respectively. Other factors boosting the regional market growth are the rising awareness of the disorder and its various treatments, technological advancements for accurate diagnosis, greater purchasing power and higher expenditure on healthcare, new drug development and launches, and increasing number of drug approvals.
Key players are adopting strategies such as mergers and acquisitions, partnerships, and regional expansion to stand out as strong competitors in the market. Recent product launches, ongoing clinical trials, and FDA approvals are other strategies competitors are using to distinguish themselves from the rest.
For instance –
In March 2019, BioPharmX Corporation completed enrolment of its Phase IIb clinical trial with BPX-041, a novel topical gel formulation of fully solubilized minocycline for the treatment of papulopustular rosacea.
In April 2019, Akorn, Inc. received a new Abbreviated New Drug Application (ANDA) approval from the FDA for Loteprednol Etabonate Ophthalmic Suspension. The product is indicated for the treatment of post-operative inflammation following ocular surgery and the treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea.
In December 2018, Aclaris Therapeutics, a dermatologist-led biopharmaceutical company focused on medical dermatology and immunology, completed its previously announced $65 million acquisition of the worldwide rights to Rhofade (oxymetazoline hydrochloride), from Allergan plc. Rhofade was approved in January 2017 for the topical treatment of persistent facial erythema (redness) associated with rosacea in adults.
In November 2018, Foamix Pharmaceuticals’ topical antibiotic for rosacea met its co-primary endpoints in two Phase III trials. The drug achieved “treatment success” in about half of the 1,522 patients enrolled in the trials and decreased the number of inflammatory lesions from baseline. With positive Phase III data, Foamix’s rosacea antibiotic is on track for 2019 NDA.
Get your free sample proposal with a single click!